Off-target pharmacological activity at various kinases: Potential functional and pathological side effects

J Pharmacol Toxicol Methods. 2023 Sep-Oct:123:107468. doi: 10.1016/j.vascn.2023.107468. Epub 2023 Aug 6.

Abstract

In drug discovery, during the lead optimization and candidate characterization stages, novel small molecules are frequently evaluated in a battery of in vitro pharmacology assays to identify potential unintended, off-target interactions with various receptors, transporters, ion channels, and enzymes, including kinases. Furthermore, these screening panels may also provide utility at later stages of development to provide a mechanistic understanding of unexpected safety findings. Here, we present a compendium of the most likely functional and pathological outcomes associated with interaction(s) to a panel of 95 kinases based on an extensive curation of the scientific literature. This panel of kinases was designed by AbbVie based on safety-related data extracted from the literature, as well as from over 20 years of institutional knowledge generated from discovery efforts. For each kinase, the scientific literature was reviewed using online databases and the most often reported functional and pathological effects were summarized. This work should serve as a practical guide for small molecule drug discovery scientists and clinical investigators to predict and/or interpret adverse effects related to pharmacological interactions with these kinases.

Keywords: Activation; Drug Discovery; Functional; Inhibition; Interaction; Kinase; Off-target; Pathological; Safety; Side effect; Table.

MeSH terms

  • Databases, Factual
  • Drug Discovery*